Sérgio Vencio, MD, PhD, MSc, Institute of Pharmaceutical Sciences (ICF), Brazil
Marcello Casaccia Bertoluci, MD, PhD, Universidade Federal do Rio Grande do Sul, Brazil
Submission Status: Open | Submission Deadline: 31 May 2024
Diabetology & Metabolic Syndrome is calling for submissions to our collection on Immunotherapy in type 1 diabetes. Type 1 diabetes is an autoimmune disease and characterize by the cell death of islet β-cells by patient’s immune system. Although discovery of insulin and its administration remained as only possible therapy, risk of long-term effects on eye and kidney along with chances of mortality remains concerning. Unfortunately, most data regarding immunotherapy are at the experimental level and only pre-clinical trial results are available. More research is needed to conclude its safety and efficacy in larger populations. However, in future, immunotherapy remains as the hope for treating Type 1 diabetes without insulin administration.
Image credit: © Gilnature / Getty Images / iStock